-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Initiates Coverage On Belite Bio with Overweight Rating, Announces Price Target of $191

Benzinga·01/06/2026 15:45:58
語音播報
Morgan Stanley analyst Judah Frommer initiates coverage on Belite Bio (NASDAQ:BLTE) with a Overweight rating and announces Price Target of $191.